Bann CM, Fehnel S, Gagnon DD. Development and validation of the diabetic foot ulcer scale-short form (DFS-SF). Pharmacoeconomics. 2003 Jan 1;21(17):1277-90.
Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003 Jan 1;21(12):839-51.
McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.
Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost-effectiveness of zanamivir for the treatment of influenza in a high-risk population in Australia. Pharmacoeconomics. 2000 Jun;17(6):611-20. doi: 10.2165/00019053-200017060-00007.
Sculpher M, Palmer MK, Heyes AE. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 Apr;17(4):361-70.
McKenna SP, Doward LC. A review of quality of life in Alzheimer's disease. Parts 1 and 2: issues in assessing disease impact and drug effects. Pharmacoeconomics. 1999 Oct;16(4):417-9.
Whalley D, McKenna SP. Measuring quality of life in patients with depression or anxiety. Pharmacoeconomics. 1995 Oct;8(4):305-15.
McKenna SP, Doward LC. Quality-of-life assessment of adults with growth hormone deficiency: implications for drug therapy. Pharmacoeconomics. 1994 Nov 1;6(5):434-41.
Milunsky A, Jick SS, Bruell CL, MacLaughlin DS, Tsung YK, Jick H, Rothman KJ, Willett W. Predictive values, relative risks and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies. New epidemiologic data. Am J Obstet Gynecol. 1989 Aug 1;161(2):291-7. doi: 10.1016/0002-9378(89)90501-2
Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol. 1981 Jan 1;139(1):47-51.